In this context, targeted, case-specific exceptions for evidence-based obesity treatment can be a measured approach that supports employee health while allowing plan sponsors to thoughtfully evaluate whether existing exclusions remain appropriate as standards continue to evolve
Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety & efficacy of Retatrutide, a first-in-class GIP, GLP-1 & glucagon triple hormone receptor agonist, in adults with obesity or overweight & knee osteoarthritis
Interestingly, the Nrf2-mediated antioxidant response pathway is highly activated in FH-mutant cells (Ooi et al., 2011)
Additional Safety Information Semaglutide (Wegovy, Ozempic ), tirzepatide (Zepbound), orforglipron (Foundayo), liraglutide (Saxenda) Contraindications Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)